A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
- Summary
- This is a phase II clinical study evaluating the safety, tolerability, pharmacokinetics and antitumor efficacy of AK146D1 in combination with AK112 or other anticancer therapies in patients with advanced Non-Small Cell Lung Cancer.
- Short title
- A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
- Official title
- A Phase II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antitumor Efficacy of AK146D1 in Combination With AK112 or Other Anticancer Therapies in Patients With Advanced Non-Small Cell Lung Cancer
- Control arm
- Open label
- Registry reports results
- Listing at source
- Listed
- Recruitment status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Completion date
- 2029-05-30
- First posted
- 2026-06-25
- Registry last updated
- 2026-07-14
- Primary completion date
- 2027-08-30
- Start date
- 2026-07-10
- Participants
- Participant count basis
- Estimated
- Planned participants
- Protocol amendments
- Number of sites
- Data monitoring committee
- Registry sponsor category
- Industry
- Lead sponsor
- Akeso
- Source registry
- ClinicalTrials.gov
- Registry ID
- NCT07669779
- ClinicalTrials.gov ID
- NCT07669779
- Registry record
- Open registry record
- Allocation
- Not randomised
- Model
- Parallel groups
- Purpose
- Treatment
- Masking
- No masking
Number of participants with dose limiting toxicities (DLTs)
Timeframe: During the first 3 weeks of treatment in Safety Run-in Phase.
DLTs are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug.
Number of participants with adverse events (AEs)
Timeframe: From the time of signing informed consent form through 30 days(for AEs) or 90 days(for SAEs) after the last dose of study drug.
AEs refer to any untoward medical occurrence or deterioration of existing medical events after the participants sign the ICFs, whether or not considered related to the study treatment.
Objective Response Rate (ORR) assessed by investigator per RECIST v1.1
Timeframe: Up to approximately 2 years.
ORR is the proportion of participants with complete response(CR) or partial response(PR) , assessed based on RECIST v1.1.
Progression Free Survival (PFS) assessed by investigator per RECIST v1.1
Timeframe: Up to approximately 2 years.
PFS is defined as the time from the start of treatment until the first documentation of disease progression (based on RECIST Version 1.1) or death due to any cause, whichever occurs first.
Disease Control Rate (DCR) assessed per RECIST v1.1
Timeframe: Up to approximately 2 years.
DCR is defined as the proportion of participants with CR, PR, or SD, assessed based on RECIST v1.1.
Duration of response (DoR) assessed by the investigator per RECIST v1.1
Timeframe: Up to approximately 2 years.
DoR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST Version 1.1) or death due to any cause, whichever occurs first.
Time to response (TTR) assessed by the investigator per RECIST v1.1
Timeframe: Up to approximately 2 years.
TTR is defined as the time to objective response based on RECIST v1.1.
Overall survival (OS)
Timeframe: Up to approximately 2 years.
OS is defined as the time from the first dose to death from any cause.
Serum PK concentration of AK146D1 and AK112
Timeframe: From pre-dose to the end of the last dose, an average of 6 months.
Serum PK concentration of AK146D1 and AK112 in participants after administration.
Anti-drug antibodies (ADA)
Timeframe: From pre-dose to 30 days post end of treatment.
The number and percentage of participants with detectable anti-drug antibodies (ADA)
- Sex
- All
- Age groups
- Adults, Older adults
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Healthy volunteers
- No
- Be able to understand and voluntarily sign the written informed consent form.
- Aged of ≥ 18 years and ≤75 years.
- ECOG PS 0 or 1.
- The expected lifespan is ≥3 months.
- Patients with histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) who are not eligible for curative surgical resection and cannot receive definitive concurrent or sequential chemoradiotherapy.
- At least one measurable non-brain lesion according to RECIST v1.1.
- Have sufficient organ function.
- Females subjects must not be pregnant at screening or have evidence of non-childbearing potential. Agree to use medically accepted methods of contraception.
- NSCLC mixed with a component of small cell lung cancer, neuroendocrine carcinoma, or carcinosarcoma.
- Having other active malignancies within 3 years.
- Currently participating in another interventional clinical study.
- Presence of active metastases to the central nervous system. For patients with asymptomatic brain metastasis or stable symptoms after treatment can be included.
- Having received any treatment targeting Trop2 or Nectin4.
- Prior chemotherapy or antibody-drug conjugate (ADC) therapy targeting topoisomerase I inhibitors.
- Receipt of systemic anti-tumor therapy (including chemotherapy, immunotherapy, biological agents, etc.) within 4 weeks (or 5 half-lives of the drug, whichever is longer) prior to the first dose.
- Toxicity of previous antineoplastic therapy has not resolved to NCI CTCAE 6.0 grade 1 or lower.
- Subjects with clinically significant cardiovascular or cerebrovascular diseases or risks.
- Subjects with active autoimmune diseases requiring systemic treatment within 2 years.
- Receipt of systemic anti-infective therapy within 2 weeks prior to the first dose.
- Known to be positive for HIV and other infections.
- Previous history of severe hypersensitivity reactions.
- Live attenuated vaccines were received within 4 weeks.
- Subjects with a history of mental illness and incapacitated or limited capacity.
- Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments.
- SunYat-sen University Cancer CenterGuangzhou, ChinaRecruiting
Related records
Drugs (4)
Lead sponsors (1)
Conditions (1)
- Non-small cell lung carcinoma Primary condition